wegovy

Hims & Hers Health, Inc. (NYSE:HIMS) shares popped after the company released its third-quarter earnings report after Monday's closing bell. Hims said it is in active discussions to make Novo Nordisk A/S (NYSE:NVO) oral Wegovy and Wegovy injections available through its platform. HIMS stock...

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its...

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that...

Hims & Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum. HIMS is encountering selling pressure. See the trading setup...

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy. HIMS is taking a hit from negative sentiment. See...

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals. The firm’s shares...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand. What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent...

Telehealth darling Hims & Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable. But is the plunge a chance to swipe right on the dip, or should investors ghost the stock altogether? The high...

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth. The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on...

Eli Lilly and Company’s (NYSE:LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE:NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants treated with tirzepatide (Zepbound) achieved an average weight loss of 20.2%, compared to 13.7...

Novo Nordisk A/S (NYSE:NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables. What Happened: On Wednesday, during Novo’s first quarter earnings call...

Hims & Hers Health Inc. (NYSE:HIMS) is suddenly looking like the hottest prescription in town – up 220% in the past year and turning heads with a bold new partnership that might just reshape digital healthcare. The company announced a long-term collaboration with pharmaceutical...

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. President Donald Trump expressed confidence in reaching agreements with both the European Union and China. On Thursday, the Dow Jones Industrial Average fell 1.3% to close at 39,142.23....

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...